Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Britain Courts Anthropic Amid US Defense Department Dispute 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
NEW YORK, Sept. 27, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) securities between June 24, 2015 and July 25, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/tokai-pharmaceuticals-inc. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, Defendants issued false and/or misleading statements to investors and/or failed to disclose that: (1) there were noteworthy structural problems with ARMOR3-SV, the trial design for Tokai's pivotal Phase 3 Galeterone study, (2) accordingly, ARMOR3-SV would probably not meet its primary endpoint; (3) therefore, the likelihood of Galeterone's commercialization was not as probable as Tokai had told investors; and (4) consequently, Tokai's financial statements were false and misleading and/or lacked a reasonable basis.
Additionally, on July 26, 2016, Tokai announced it would end a late-stage trial of Galeterone, saying it believed the stage 3 study would not meet its primary endpoint. Following this news, Tokai shares fell from $5.20 on July 25, 2016, to a close of $1.10 on July 26, 2016.
If you suffered a loss in Tokai you have until September 30, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/tokai-pharmaceuticals-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
